BRCC3 and astrocytoma (excluding glioblastoma): The results from immunohistochemistry indicated that tumor cells in grade I-III astrocytoma and grade IV GBM displayed a strong BRCC3 immunoreactivity (Fig. 1B-E, arrows), whereas BRCC3 staining was weak in normal brain tissues (Fig. 1A, arrows).